

Laura E Raffals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4917382/publications.pdf>

Version: 2024-02-01

67
papers

1,569
citations

331538

21
h-index

330025

37
g-index

67
all docs

67
docs citations

67
times ranked

1987
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1663-1666.e3.	2.4	3
2	Primary Sclerosing Cholangitis-associated Pouchitis: A Distinct Clinical Phenotype. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e964-e973.	2.4	13
3	The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). <i>Inflammatory Bowel Diseases</i> , 2022, 28, 192-199.	0.9	11
4	Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis. <i>Crohn's & Colitis 360</i> , 2022, 4, .	0.5	2
5	Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1560-1568.	1.9	12
6	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 35-53.	2.3	10
7	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
8	Editorial: what is normal function of a pelvic pouch? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1454-1455.	1.9	0
9	Author's Reply to Pestana et al. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor Inhibitors?" <i>American Journal of Clinical Dermatology</i> , 2022, 23, 593-594.	3.3	1
10	Letter: normalizing the ileoanal pouch—more than a one-step technique. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 176-177.	1.9	0
11	The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1270-1276.	0.9	11
12	Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1285-1287.e1.	2.4	16
13	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 594-602.	0.9	6
14	Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 616-617.	2.4	58
15	Virtual Interviews During the COVID-19 Pandemic: A Survey of Advanced Endoscopy Fellowship Applicants and Programs. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2021, 23, 159-168.	0.4	8
16	Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1968-1974.	0.9	5
17	The extent of colorectal resection and short-term outcomes in patients with ulcerative colitis. <i>Updates in Surgery</i> , 2021, 73, 1429-1434.	0.9	3
18	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	1

#	ARTICLE	IF	CITATIONS
19	The Use of Biologics for the Treatment of Esophageal Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1544-1547.	0.9	0
20	Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis—a single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 217-218.	1.9	1
21	Survey Finds Gender Disparities Impact Both Women Mentors and Mentees in Gastroenterology. <i>American Journal of Gastroenterology</i> , 2021, 116, 1876-1884.	0.2	13
22	Approach to medical therapy in perianal Crohn's disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 3693-3704.	1.4	9
23	Vulvar Crohn's Disease: Clinical Features and Outcomes. <i>American Journal of Gastroenterology</i> , 2021, 116, 2296-2299.	0.2	5
24	Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1089-1097.	0.9	19
25	Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 774-779.	0.9	11
26	De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 252-253.	2.4	37
27	Prospective multicenter study to evaluate capsule endoscopy competency using a validated assessment tool. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1140-1145.	0.5	8
28	Self-administered Fecal Microbial Transplants—What Could Possibly Go Wrong?. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	0
29	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis</i> 360, 2020, 2, otaa039.	0.5	8
30	An Update on the Medical Management of Inflammatory Pouch Complications. <i>American Journal of Gastroenterology</i> , 2020, 115, 1439-1450.	0.2	21
31	Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1291-1305.	0.9	2
32	Program Directors' Perspectives of Gastroenterology and Hepatology Fellowship Application. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2735-2736.	1.1	3
33	Medical Education Interest, Exposure, and Career Planning in Subspecialty Trainees. <i>Medical Science Educator</i> , 2020, 30, 1011-1014.	0.7	2
34	A Comprehensive Approach to Pouch Disorders. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 460-471.	0.9	27
35	Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 580-586.	0.9	40
36	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1171.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Impact of a Multidisciplinary eBoard on the Management of Patients With Complex Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	1
38	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease: Single-Center Series. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	6
39	Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1036-1043.	0.6	11
40	Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. <i>Journal of Pediatric Surgery</i> , 2019, 54, 2162-2165.	0.8	15
41	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1655-1668.e3.	2.4	214
42	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1569-1576.	0.9	50
43	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	2
44	Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1352-1362.	0.7	23
45	An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 902-913.	0.9	72
46	Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 818-823.	2.4	14
47	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 767-774.	0.9	60
48	Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2019, 20, 1317-1322.	1.0	7
49	De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 452-457.	0.6	29
50	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 402-407.	0.6	66
51	Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1074-1081.	0.9	27
52	Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 137-144.	0.6	40
53	Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 528-533.	2.4	23
54	Depression Is Associated With More Aggressive Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 80-85.	0.2	121

#	ARTICLE	IF	CITATIONS
55	Response to Levenstein and Prantera. <i>American Journal of Gastroenterology</i> , 2018, 113, 1559.	0.2	0
56	Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1582-1588.	0.9	31
57	Tuberculosis of the gastrointestinal tract and associated viscera. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2018, 12, 1-8.	0.6	32
58	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878361.	1.4	11
59	Response to Dai et al. and Gracie et al.. <i>American Journal of Gastroenterology</i> , 2018, 113, 774-775.	0.2	0
60	AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1191-1199.	0.6	14
61	Nonrelaxing Pelvic Floor Dysfunction Is an Underestimated Complication of Ileal Pouch-Anal Anastomosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1242-1247.	2.4	43
62	Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3557-3562.	1.1	18
63	The Microbiome in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 481-492.	1.0	45
64	Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 185-190.	0.6	114
65	Pouchitis Is a Common Complication in Patients With Familial Adenomatous Polyposis Following Ileal Pouch-Anal Anastomosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1296-1301.	2.4	40
66	Navigating the Microbial Basis of Inflammatory Bowel Diseases: Seeing the Light at the End of the Tunnel. <i>Gut and Liver</i> , 2016, 10, 502-508.	1.4	14
67	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1197-1200.	2.4	47